Prot# CSMS995 804: A Randomized, Controlled Study on the Efficacy and Safety of Sandostatin LAR in the Therapy of Patients with Moderately Severe or Severe Non-Proliferative Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR)

Project: Research project

Project Details

StatusFinished
Effective start/end date12/1/99 → 12/31/05

Funding

  • Novartis Pharmaceuticals Corporation (SMS995 804)